Modeling the effectiveness of One Health interventions against the zoonotic hookworm .

Hookworm disease is a major global public health concern, annually affecting 500-700 million of the world's poorest people. The World Health Organization is targeting the elimination of hookworm as a public health problem by 2030 using a strategy of mass drug administration (MDA) to at-risk human populations. However, in Southeast Asia and the Pacific the zoonotic hookworm species, , is endemic in dogs and commonly infects people.

Risk profiling and efficacy of albendazole against the hookworms and in Cambodia to support control programs in Southeast Asia and the Western Pacific.

Hookworm disease is endemic throughout many parts of the Asia Pacific, despite targeted control programs of at-risk populations. The success of these programs has been hindered by the limited efficacy of widely-used mebendazole, rapid re-infection rates linked to persistent reservoirs of untreated people and dogs, and the low sensitivity of conventional coprodiagnostic techniques employed. Here, we used standard faecal flotation (SFF) and a multiplex qPCR (mqPCR) assay to calculate and compare species-specific cure and egg reduction rates of single dose albendazole (400 mg) against hookworm infections at community level.

Comparative study of femtosecond laser-assisted cataract surgery and conventional phacoemulsification in vitrectomized eyes.

Importance: To compare the safety and outcomes of femtosecond laser-assisted cataract surgery (FLACS) and conventional phacoemulsification in post-vitrectomy eyes.

Background: To compare visual outcomes and adverse outcomes of FLACS and conventional phacoemulsification in vitrectomized eyes.

Design: Single surgeon, retrospective study set in a private clinic in Auckland, New Zealand.

Prevalence predictions for age-related macular degeneration in New Zealand have implications for provision of healthcare services.

Aim: To predict the prevalence of age-related macular degeneration (AMD) in New Zealand from 2014 through to 2026.

Method: Prevalence estimates for AMD in New Zealand for 2014 through to 2026 were generated by applying ethnic prevalence rate estimates for any, early and late AMD to New Zealand population projections for European, Maori, Pacific and Asian peoples.

Results: The prevalence of any AMD in New Zealand for the 45-85 year age group is estimated to be 184,400 in 2014 (10.